LL-37 vs VIP
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Also: Vasoactive Intestinal Peptide, Aviptadil
A naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | LL-37 | VIP |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. | VIP binds to VPAC1 and VPAC2 receptors, triggering anti-inflammatory cascades. It relaxes smooth muscle, vasodilates, inhibits pro-inflammatory cytokines, and promotes regulatory T-cell function. Has broad immunomodulatory effects. |
| Common Dosing | 100-200 mcg daily Once daily | 50-100 mcg intranasal daily 1-2x daily, intranasal |
| Administration | Subcutaneous injection or topical | IV infusion, inhaled, or intranasal |
| Typical Duration | Variable by protocol | Variable by indication |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. | Clinical trials for COVID-19 ARDS showed promising results. Research demonstrates benefits in pulmonary arterial hypertension. Studies show potential for autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease. |
Frequently Asked Questions: LL-37 vs VIP
What is the difference between LL-37 and VIP?
LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. VIP is a immune peptide that a naturally occurring peptide with immunomodulatory and anti-inflammatory effects. being studied for ards, pulmonary hypertension, and autoimmune conditions. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or VIP?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while VIP is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and VIP be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and VIP together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of LL-37 and VIP is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.